The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French.
In the event of any conflict between the English and French versions, the English version shall prevail.

This List shall come into effect on 1 January 2017
IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3.

PROHIBITED SUBSTANCES

S0 NON-APPROVED SUBSTANCES
Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

S1 ANABOLIC AGENTS
Anabolic agents are prohibited.

1. ANABOLIC ANDROGENIC STEROIDS (AAS)
a. Exogenous* AAS, including:

Mestanolone;
Mesterolone;
Metandienone [17β-hydroxy-17α-methylandrosta-1,4-dien-3-one];
Metenolone;
Methandriol;
Methasterone [17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one];
Methylidenolone [17β-hydroxy-17α-methylenestra-4,9-dien-3-one];
Methyl-1-testosterone [17β-hydroxy-17α-methyl-5α-androst-1-en-3-one];
Methylnortestosterone [17β-hydroxy-17α-methylenestra-4-en-3-one];
Methyltestosterone;
Metribolone (17α-hydroxy-17α-methylenestra-4,9,11-trien-3-one);
Mibolerone;
Norboletheone;
Norclostebol;
Norethandrolone;
Oxabolone;
Oxandrolone;
Oxymesterone;
Oxymetholone;
Prostanozol [17β-[[tetrahydropyran-2-yl]oxy]-1'H-pyrazolo[3,4,2,3]-5α-androstan-3-one];
Quinbolone;
Stanozolol;
Stenbolone;
Tetrahydrogestrinone [17-hydroxy-18α-homo-19-nor-17α-pregna-4,9,11-trien-3-one];
Trenbolone [17β-hydroxyestr-4,9,11-trien-3-one];
and other substances with a similar chemical structure or similar biological effect(s).

1-Androstenediol (5α-androst-1-ene-3β,17β-diol);
1-Androstenedione (5α-androst-1-ene-3,17-dione);
1-Testosterone [17β-hydroxy-5α-androst-1-en-3-one];
4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one);
Bolanadiol (estr-4-ene-3β,17β-diol);
Bolasterone;
Calusterone;
Clostebol;
Danazol [(1,2)oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol];
Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one);
Desoxymethyltestosterone [17α-methyl-5α-androst-2-en-17β-ol];
Drostanolone;
Ethylestrenol [19-norpregna-4-en-17β-ol];
Fluoxymesterone;
Formebolone;
Furazabol [17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol];
Gestrinone;

1-Androstenediol (5α-androst-1-ene-3β,17β-diol);
1-Androstenedione (5α-androst-1-ene-3,17-dione);
1-Testosterone [17β-hydroxy-5α-androst-1-en-3-one];
4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one);
Bolanadiol (estr-4-ene-3β,17β-diol);
Bolasterone;
Calusterone;
Clostebol;
Danazol [(1,2)oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol];
Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one);
Desoxymethyltestosterone [17α-methyl-5α-androst-2-en-17β-ol];
Drostanolone;
Ethylestrenol [19-norpregna-4-en-17α-ol];
Fluoxymesterone;
Formebolone;
Furazabol [17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol];
Gestrinone;
b. Endogenous** AAS when administered exogenously:

- 19-Norandrostenediol (estr-4-ene-3,17-diol);
- 19-Norandrostenedione (estr-4-ene-3,17-dione);
- Androstenediol (androst-5-ene-3β,17β-diol);
- Androstenedione (androst-4-ene-3,17-dione);
- Boldenone;
- Boldione (androsta-1,4-diene-3,17-dione);
- Dihydrotestosterone (17β-hydroxy-5α-androstan-3-one);
- Nandrolone (19-nortestosterone);
- Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one);
- Testosterone;

and their metabolites and isomers, including but not limited to:

- 3β-Hydroxy-5α-androstan-17-one;
- 5α-Androst-2-ene-17-one;
- 5α-Androstane-3α,17α-diol;
- 5α-Androstane-3α,17β-diol;
- 5α-Androstane-3β,17α-diol;
- 5α-Androstane-3β,17β-diol;
- 5β-Androstane-3α,17β-diol;
- 7α-Hydroxy-DHEA;
- 7β-Hydroxy-DHEA;
- 4-Androstenediol (androst-4-ene-3β,17β-diol);
- 5-Androstenedione (androst-5-ene-3,17-dione);
- 7-Keto-DHEA;
- 19-Norandrosterone;
- 19-Nortiocolanone;
- Androst-4-ene-3α,17α-diol;
- Androst-4-ene-3α,17β-diol;
- Androst-4-ene-3β,17α-diol;
- Androst-5-ene-3α,17α-diol;
- Androst-5-ene-3α,17β-diol;
- Androst-5-ene-3β,17α-diol;
- Androsterone;
- Epi-dihydrotestosterone;
- Epitosterone;
- Etioclanolone.

2. OTHER ANABOLIC AGENTS

Including, but not limited to:

- Clenbuterol;
- Selective androgen receptor modulators (SARMs, e.g. andarine and ostarine);
- Tibolone;
- Zeranol;
- Zilpaterol.

For purposes of this section:

* “exogenous” refers to a substance which is not ordinarily produced by the body naturally.

** “endogenous” refers to a substance which is ordinarily produced by the body naturally.

S2 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

1. Erythropoietin-Receptor agonists:

1.1 Erythropoiesis-Stimulating Agents (ESAs) including e.g. Darbepoietin (dEPO); Erythropoietins (EPO); EPO-Fc; EPO-mimetic peptides (EMP), e.g. CNTO 530 and peginesatide; GATA inhibitors, e.g. K-11706; Methoxy polyethylene glycol-epoetin beta (CERA); Transforming Growth Factor-β (TGF-β) inhibitors, e.g. sotatercept, luspatercept;

1.2 Non-erythropoietic EPO-Receptor agonists, e.g. ARA-290; Asialo EPO; Carbamylated EPO.

2. Hypoxia-inducible factor (HIF) stabilizers, e.g. cobalt, molidustat and roxadustat (FG-4592); and HIF activators, e.g. argon and xenon.
3. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, e.g. buserelin, gonadorelin and leuprorelin, in males.

4. Corticotrophins and their releasing factors, e.g. corticorelin.

5. Growth Hormone (GH) and its releasing factors including:
   • Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1295, sermorelin and tesamorelin;
   • Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin and ipamorelin;
   • GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-6, hexarelin, and pralmorelin (GHRP-2).

Additional prohibited growth factors:

- Fibroblast Growth Factors (FGFs);
- Hepatocyte Growth Factor (HGF);
- Insulin-like Growth Factor-1 (IGF-1) and its analogues;
- Mechano Growth Factors (MOFs);
- Platelet-Derived Growth Factor (PDGF);
- Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity, or fibre type switching.

**BETA-2 AGONISTS**

All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: Fenoterol; Formoterol; Higenamine; Indacaterol; Olodaterol; Procateler; Reproterol; Salbutamol; Salmeterol; Terbutaline; Vilanterol.

**Except:**
- Inhaled salbutamol: maximum 1600 micrograms over 24 hours, not to exceed 800 micrograms every 12 hours;
- Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours;
- Inhaled salmeterol: maximum 200 micrograms over 24 hours.

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an *Adverse Analytical Finding (AAF)* unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic dose (by inhalation) up to the maximum dose indicated above.

**HORMONE AND METABOLIC MODULATORS**

The following hormone and metabolic modulators are prohibited:

1. Aromatase inhibitors including, but not limited to: 4-Androsten-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Exemestane; Formestane; Letrozole; Testolactone.

2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Raloxifene; Tamoxifen; Toremifene.

3. Other anti-estrogenic substances including, but not limited to: Clomiphene; Cyclofenil; Fulvestrant.
4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors.

5. Metabolic modulators:
   5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. GW 1516;
   5.2 Insulins and insulin-mimetics;
   5.3 Meldonium;
   5.4 Trimetazidine.

DIURETICS AND MASKING AGENTS
The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s).

Including, but not limited to:
- Desmopressin; probenecid; plasma expanders, e.g. glycerol and intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol;
- Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan.

Except:
- Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide);
- Local administration of felypressin in dental anaesthesia.

The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent.

PROHIBITED METHODS

MANIPULATION OF BLOOD AND BLOOD COMPONENTS
The following are prohibited:
1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.

2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation.

3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

CHEMICAL AND PHYSICAL MANIPULATION
The following are prohibited:
1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Urine substitution and/or adulteration, e.g. proteases.

2. Intravenous infusions and/or injections of more than 50 mL per 6 hour period except for those legitimately received in the course of hospital admissions, surgical procedures or clinical investigations.

GENE DOPING
The following, with the potential to enhance sport performance, are prohibited:
1. The transfer of polymers of nucleic acids or nucleic acid analogues.

2. The use of normal or genetically modified cells.
IN ADDITION TO THE CATEGORIES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CATEGORIES ARE PROHIBITED IN-COMPETITION:

PROHIBITED SUBSTANCES

**Stimulants**

All stimulants, including all optical isomers, e.g. \(d\)- and \(l\)- where relevant, are prohibited.

Stimulants include:

- **a: Non-Specified Stimulants:**
  - Adrafinil;
  - Amfepramone;
  - Amfetamine;
  - Amfetaminil;
  - Amiphenazole;
  - Benfluorex;
  - Bromantan;
  - Clobenzorex;
  - Cocaine;
  - Cropropamide;
  - Crotetamide;
  - Fenflamine;
  - Fenbutrazate;
  - Fencamfamin;
  - Fencamfamin; [4-phenylpiracetam | carphedon];
  - Furfenorex;
  - Lisdexamfetamine;
  - Mefenorex;
  - Mephentermine;
  - Mesocarb;
  - Metamfetamine (d-);
  - \(\rho\)-methylamphetamine;
  - Modafinil;
  - Norfenfluramine;
  - Phendimetrazine;
  - Phentermine;
  - Prenylamine;
  - Prolintane.

A stimulant not expressly listed in this section is a *Specified Substance*.

- **b: Specified Stimulants.**
  - Including, but not limited to:
    - 4-Methylhexan-2-amine (methylhexaneamine);
    - Benzphetamine;
    - Cathine**;
    - Cathinone and its analogues, e.g. mephedrone, methedrone, and \(\alpha\)-pyrrolidinovalerophenone;
    - Dimethylamphetamine;
    - Ephedrine***;
    - Epinephrine**** (adrenaline);
    - Etamivan;
    - Etilamfetamine;
    - Etilefrine;
    - Famprofazone;
    - Fenbutrazate;
    - Fencamfamin;
    - Heptaminol;
    - Hydroxyamphetamine [parahydroxyamphetamine];
    - Isomethetene;
    - Levmetamfetamine;
    - Meclofenoxate;
    - Methylenedioxymethamphetamine;
    - Methylephedrine***;
    - Methylphenidate;
    - Nikethamide;
    - Norfenefrine;
    - Octopamine;
    - Oxilofrine [methylsynephrine];
    - Pemoline;
    - Pentetrazol;
    - Phenethylamine and its derivatives;
    - Phenmetrazine;
    - Phenpromethamine;
    - Propylhexedrine;
    - Pseudoephedrine*****;
Selegiline; 
Sibutramine; 
Strychnine; 
Tetramphetamine (methylenedioxyamphetamine); 
Tuaminoheptane;

and other substances with a similar chemical structure or similar biological effect(s).

** Except: **
- Clonidine;
- Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2017 Monitoring Program*.
* Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2017 Monitoring Program, and are not considered Prohibited Substances.

** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.

*** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.

**** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents.

***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

---

**NARCOTICS**

Prohibited:
- Buprenorphine;
- Dextroromamide;
- Diamorphine (heroin);
- Fentanyl and its derivatives;
- Hydromorphone;
- Methadone;
- Morphine;
- Nicomorphine;
- Oxycodone;
- Oxymorphone;
- Pentazocine;
- Pethidine.

---

**CANNABINOIDs**

Prohibited:
- Natural, e.g. cannabis, hashish and marijuana, or synthetic Δ9-tetrahydrocannabinol (THC).

---

**GLUCOCORTICOIDS**

All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular, or rectal routes.
**ALCOHOL**

Alcohol (ethanol) is prohibited *In-Competition* only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10 g/L.

- Air Sports (FAI)
- Archery (WA)
- Automobile (FIA)
- Powerboating (UIM)

---

**BETA-BLOCKERS**

Beta-blockers are prohibited *In-Competition* only, in the following sports, and also prohibited *Out-of-Competition* where indicated.

- Archery (WA)*
- Automobile (FIA)
- Billiards (all disciplines) (WCBS)
- Darts (WDF)
- Golf (IGF)
- Shooting (ISSF, IPC)*
- Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air
- Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting, and variable weight apnoea.

*Also prohibited *Out-of-Competition*

Including, but not limited to:

- Acebutolol;
- Alpenolol;
- Atenolol;
- Betaxolol;
- Bisoprolol;
- Bunolol;
- Carteolol;
- Carvedilol;
- Celiprolol;
- Esmolol;
- Labetalol;
- Levobunolol;
- Metipranolol;
- Metoprolol;
- Nadolol;
- Oxprenolol;
- Pindolol;
- Propranolol;
- Sotalol;
- Timolol.